Small Cell Lung Cancer
Conditions
Keywords
SCLC, Etoposide, SNP, Topo, CYP, Genotype, Oncology, Genetics, Lung, Cancer
Brief summary
Explore the relationship between drug target topoisomerase II gene single nucleotide polymorphisms and Etoposide (VP-16) therapeutic-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene single nucleotide polymorphisms and Etoposide (VP-16) side-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes.
Detailed description
The usual approach group, after lung tissue biopsy, 300 double blind random group separated SCLC patients currently used the Chemotherapy on ETOPOSIDE capsule, it will try to look for the relationship between the ETOPOSIDE therapeutic efficacy and the Topoisomerase II SNP Genotyping, and the relationship between the ETOPOSIDE therapeutic safety and the CYP4503A4 SNP Genotyping, based on Oxford precisely sequencing drug targets' genes. The study approach group, after lung tissue biopsy, 300 double blind random group separated SCLC patients currently used the Chemotherapy on China Import Etoposide Capsule, it will try to look for the relationship between the ETOPOSIDE therapeutic efficacy and the Topoisomerase II SNP Genotyping, and the relationship between the ETOPOSIDE therapeutic safety and the CYP4503A4 SNP Genotyping, based on Oxford precisely sequencing drug targets' genes. * 1\) Detect drug target whole gene precision sequence of everyone patient for all 600 recruited double blind SCLC patients. * 2\) Mutually compare everyone patient drug target whole gene precision sequence for a total of 600 recruited double blind SCLC patients. * 3\) Calculate drug target gene SNPs in all 600 recruited double blind SCLC patients. * 4\) Correlate everyone patient drug target gene SNP to everyone patient drug efficacy. * 5\) Correlate everyone patient drug target gene SNP to everyone patient drug safety. * 6\) Mutually compare the usual approach group SNPs (300 double blind random group separated SCLC patients) with the study approach group SNPs (300 double blind random group separated SCLC patients). * 7\) Confirm the relationship between drug target gene SNPs and drug efficacy. * 8\) Confirm the relationship between drug target gene SNPs and drug safety.
Interventions
DRUGETOPOSIDE - Usual
Etoposide Capsule
DRUGETOPOSIDE - Study
China Import Etoposide Capsule
Sponsors
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
UnitedHealthcare
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
No-placebo and random and double blind
Intervention model description
* The usual approach group (Oral) * The study approach group (Oral) (China Import)
Eligibility
Sex/Gender
ALL
Age
24 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* Select 600 Small Cell Lung Cancer Patients who are suitable for lung tissue biopsy * Dosage Duration at least 45 days * The usual approach group - Recruit 300 double blind random group separated SCLC patients currently used the Chemotherapy on Etoposide Capsule after lung tissue biopsy, like as the usual approach group. * The study approach group - Recruit 300 double blind random group separated SCLC patients currently used the Chemotherapy on China Import Etoposide Capsule after lung tissue biopsy, like as the study approach group. The inclusion criteria: * 1\. Clinical diagnosis of Small Cell Lung Cancer (SCLC) * 2\. Clinical lung tissue biopsy diagnosis of SCLC * 3\. Suitable for enough lung tissue biopsy of SCLC * 4\. Random and double blind * 5\. Measurable disease * 6\. Adequate organ functions * 7\. Adequate performance status * 8\. Age 24 years old and over * 9\. Sign an informed consent form * 10\. Receive blood-drawing The
Exclusion criteria
* 1\. Pneumonectomy * 2\. Treatment with other anti-cancer therapies and cannot be stopped currently * 3\. Pregnancy * 4\. Breast-feeding * 5\. The patients with other serious intercurrent illness or infectious diseases * 6\. Have more than one different kind of cancer at the same time * 7\. Serious Allergy to Drugs * 8\. Clot or Bleed Tendency * 9\. Serious Risks or Serious Adverse Events of the drug product * 10\. The prohibition of drug products * 11\. Have no therapeutic effects * 12\. Follow up to the most current label
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Find Etoposide Drug Targets' SNP Genotypes which are effectiveness-associated, and which are risk-associated. | Duration at least 90 days | 1. Recruit 300 double blind random group separated SCLC patients currently used the Chemotherapy on Etoposide Capsule after lung tissue biopsy, like as the usual approach group. 2. Recruit 300 double blind random group separated SCLC patients currently used the Chemotherapy on China Import Etoposide Capsule after lung tissue biopsy, like as the study approach group. 3. Assay above every SCLC patient-specific Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her WBC cell whole genome DNA with Oxford precisely sequencing. 4. Assay above every SCLC patient-specific Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with Oxford precisely sequencing. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORHAN XU, MD/PhD/FAPCR
Medicine Invention Design, Inc. (MIDI) - IORG0007849 - NPI 1023387701
STUDY_DIRECTORHAN XU, MD/PhD/FAPCR
Medicine Invention Design, Inc. (MIDI) - IORG0007849 - NPI 1023387701
STUDY_CHAIRHAN XU, MD/PhD/FAPCR
Medicine Invention Design, Inc. (MIDI) - IORG0007849 - NPI 1023387701
Outcome results
None listed